Online citations, reference lists, and bibliographies.
← Back to Search

Le Mésothéliome Pleural Malin

J. Margery, D. Planchard
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
RésuméLe mésothéliome pleural malin (MPM) est une tumeur rare et agressive, souvent consécutive à une exposition professionnelle à l’amiante. La symptomatologie clinique et radiologique est aspécifique. Le diagnostic est apporté par l’histologie à partir de biopsies pleurales obtenues par thoracoscopie. L’irradiation des orifices chirurgicaux diagnostiques est validée par les recommandations francophones. La chirurgie par pleuropneumonectomie élargie ou par pleurectomie/décortication n’est pas recommandée en dehors d’un essai clinique. La chimiothérapie par la combinaison pemetrexed-cisplatine est le traitement de référence du MPM. Le bevacizumab est évalué dans l’essai de phase III MAPS dont les 445 inclusions se sont terminées en décembre 2013.AbstractMalignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.
This paper references
10.1016/j.athoracsur.2011.02.062
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.
J. Friedberg (2011)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.1097/JTO.0b013e3182417da5
Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group
G. Levallet (2012)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1016/J.RMED.2006.10.018
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
A. Scherpereel (2007)
10.1016/J.PNEUMO.2010.07.013
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/S0169-5002(02)00178-2
Inactivation of p16INK4a expression in malignant mesothelioma by methylation.
L. Wong (2002)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1183/09031936.00037310
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1097/MCP.0b013e32812144bb
Biomarkers for mesothelioma
A. Scherpereel (2007)
10.1183/09031936.00153611
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy
R. Damhuis (2011)
10.1136/oem.2005.023200
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
10.1073/PNAS.92.24.10854
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
A. Bianchi (1995)
10.2741/1953
WNT signaling in malignant mesothelioma.
S. Fox (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1684/bdc.2008.0566
[Environmental cancer: malignant pleural mesothelioma].
Jacques Margery (2008)
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
G. Cole (2006)
French speaking Society for Chest Medicine Experts Group (2007) Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma
A Scherpereel (2007)
10.1510/icvts.2010.251488
A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS).
T. Treasure (2011)
10.1200/jco.2009.27.15_suppl.10520
Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP).
S. Schütze (2009)
10.1510/icvts.2010.255901
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1684/BDC.2008.0566
Cancer environnemental : le mésothéliome pleural
J. Margery (2008)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/j.hlc.2010.11.045
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2011)
10.1002/ijc.24711
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005
N. Le Stang (2010)
10.1016/j.pneumo.2010.07.013
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
J. Margery (2010)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)



Semantic Scholar Logo Some data provided by SemanticScholar